Forte Biosciences (FBRX) Accumulated Expenses (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Accumulated Expenses data on file, last reported at $10.6 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 745.04% year-over-year to $10.6 million in Q1 2026; TTM through Mar 2026 was $10.6 million, a 745.04% increase from a year earlier, with the FY2025 full-year figure at $2.2 million, up 45.07% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $10.6 million, up from $2.2 million in the prior quarter.
• Over the last five years, Accumulated Expenses for FBRX reached as high as $10.6 million in Q1 2026 and fell as low as $359000.0 in Q1 2022.
• Historically, Accumulated Expenses has averaged $2.2 million across 5 years, with a median of $1.6 million in 2024.
• Across the five-year window, Accumulated Expenses sank 77.22% in 2022 and surged 745.04% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $2.0 million in 2022, then tumbled by 53.26% to $947000.0 in 2023, then soared by 63.78% to $1.6 million in 2024, then soared by 45.07% to $2.2 million in 2025, then soared by 369.47% to $10.6 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $10.6 million in Q1 2026, $2.2 million in Q4 2025, and $1.3 million in Q3 2025.